https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-26 / Vaccine 2012 Jun;30(29):4394-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-26 / Vaccine 2012 Jun;30(29):4394-72011-11-26 00:00:002019-02-15 08:52:45Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-23 / Int. J. Oncol. 2012 Mar;40(3):764-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-23 / Int. J. Oncol. 2012 Mar;40(3):764-722011-11-23 00:00:002019-02-15 08:46:36Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-16 / Cancer Immunol. Immunother. 2012 Jun;61(6):865-79
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-16 / Cancer Immunol. Immunother. 2012 Jun;61(6):865-792011-11-16 00:00:002019-02-15 08:45:53Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-502011-11-16 00:00:002021-11-15 16:57:44Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-642011-11-15 00:00:002011-11-15 00:00:00Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-07 / World Neurosurg 2012 May-Jun;77(5-6):736-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-07 / World Neurosurg 2012 May-Jun;77(5-6):736-442011-11-07 00:00:002019-02-15 08:46:33Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-02 / J. Immunol. 2011 Dec;187(11):6130-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-02 / J. Immunol. 2011 Dec;187(11):6130-422011-11-02 00:00:002019-02-15 08:40:01Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3995-4005
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3995-40052011-11-01 00:00:002019-02-15 08:46:01Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3963-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3963-72011-11-01 00:00:002019-02-15 08:39:19Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-26 / J. Biomed. Biotechnol. 2011;2011:718710
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-26 / J. Biomed. Biotechnol. 2011;2011:7187102011-10-26 00:00:002019-02-15 09:21:34Safety and clinical usage of newcastle disease virus in cancer therapy
